Furazolidone - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (2)

Targets (1)Enzymes (2)Biointeractions (3)

Identification

Name

Furazolidone

Accession Number

DB00614 (APRD00988)

Type

Small Molecule

Groups

Approved, Vet Approved

Description

A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

3-(5'-Nitrofurfuralamino)-2-oxazolidone

3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone

3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone

3-[(5-Nitrofurylidene)amino]-2-oxazolidone

3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone

5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine

Furazolidona

Furazolidone

Furazolidonum

Furoxone

FZL

N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone

N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one

Nitrofurazolidone

Nitrofurazolidonum

External IDs

USAF EA-1

Product Ingredients

Not Available

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Dependal-M	GlaxoSmithKline
Furoxone	Roberts Laboratories

Brand mixtures

Not Available

Categories

UNII

5J9CPU3RE0

CAS number

67-45-8

Weight

Average: 225.1583
Monoisotopic: 225.038570349

Chemical Formula

C₈H₇N₃O₅

InChI Key

PLHJDBGFXBMTGZ-WEVVVXLNSA-N

InChI

InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+

IUPAC Name

3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one

SMILES

[O-][N+](=O)C1=CC=C(O1)C=NN1CCOC1=O

Pharmacology

Indication

For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.

Structured Indications

Not Available

Pharmacodynamics

Furoxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms.

Mechanism of action

Furazolidone and its related free radical products are believed to bind DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug leading to high levels of mutations (transitions and transversions) in the bacterial chromosome.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
DNA	Nucleotide	yes	cross-linking/alkylation	Human	not applicable	details

Absorption

Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Furazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione.

Substrate	Enzymes	Product
Furazolidone	Not Available	beta-Hydroxyethylhydrazine	Details
Furazolidone	Not Available	3-amino-2-oxazolidone	Details

Route of elimination

Not Available

Half life

10 minutes

Clearance

Not Available

Toxicity

Reactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.

Affected organisms

Microbes (bacteria, parasites)

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	Furazolidone may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.	Experimental, Illicit
3,4-Methylenedioxyamphetamine	Furazolidone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.	Experimental, Illicit
3,4-Methylenedioxymethamphetamine	Furazolidone may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	Furazolidone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.	Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE	Furazolidone may increase the hypertensive activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.	Experimental
Acarbose	Furazolidone may increase the hypoglycemic activities of Acarbose.	Approved, Investigational
Acebutolol	Furazolidone may increase the hypotensive activities of Acebutolol.	Approved
Albiglutide	Furazolidone may increase the hypoglycemic activities of Albiglutide.	Approved
Alfentanil	Alfentanil may increase the serotonergic activities of Furazolidone.	Approved, Illicit
Aliskiren	Furazolidone may increase the hypotensive activities of Aliskiren.	Approved, Investigational
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Furazolidone.	Approved, Investigational
Alogliptin	Furazolidone may increase the hypoglycemic activities of Alogliptin.	Approved
Alprenolol	Furazolidone may increase the hypotensive activities of Alprenolol.	Approved, Withdrawn
Altretamine	Altretamine may increase the orthostatic hypotensive activities of Furazolidone.	Approved
Ambrisentan	Furazolidone may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Amineptine	Furazolidone may increase the serotonergic activities of Amineptine.	Illicit, Withdrawn
Amitriptyline	Furazolidone may increase the serotonergic activities of Amitriptyline.	Approved
Amlodipine	Furazolidone may increase the hypotensive activities of Amlodipine.	Approved
Amoxapine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Amoxapine.	Approved
Amphetamine	Furazolidone may increase the hypertensive activities of Amphetamine.	Approved, Illicit
Apomorphine	The metabolism of Apomorphine can be decreased when combined with Furazolidone.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Apraclonidine.	Approved
Arbutamine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Arbutamine.	Approved
Arformoterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Arformoterol.	Approved, Investigational
Atenolol	Furazolidone may increase the hypotensive activities of Atenolol.	Approved
Atomoxetine	Furazolidone may increase the central neurotoxic activities of Atomoxetine.	Approved
Atropine	Furazolidone may increase the hypertensive activities of Atropine.	Approved, Vet Approved
Bambuterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Bambuterol.	Approved
Benazepril	Furazolidone may increase the hypotensive activities of Benazepril.	Approved, Investigational
Bendroflumethiazide	Furazolidone may increase the hypotensive activities of Bendroflumethiazide.	Approved
Benmoxin	Furazolidone may increase the hypertensive activities of Benmoxin.	Withdrawn
Benzphetamine	Furazolidone may increase the hypertensive activities of Benzphetamine.	Approved, Illicit
Bepridil	Furazolidone may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betahistine	The serum concentration of Betahistine can be increased when it is combined with Furazolidone.	Approved
Betaxolol	Furazolidone may increase the hypotensive activities of Betaxolol.	Approved
Bethanidine	Furazolidone may increase the hypotensive activities of Bethanidine.	Approved
Bezafibrate	The risk or severity of adverse effects can be increased when Furazolidone is combined with Bezafibrate.	Approved
Bimatoprost	Furazolidone may increase the hypotensive activities of Bimatoprost.	Approved, Investigational
Bisoprolol	Furazolidone may increase the hypotensive activities of Bisoprolol.	Approved
Bosentan	Furazolidone may increase the hypotensive activities of Bosentan.	Approved, Investigational
Bretylium	Furazolidone may increase the hypotensive activities of Bretylium.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Brimonidine.	Approved
Brimonidine	Furazolidone may increase the hypotensive activities of Brimonidine.	Approved
Bromocriptine	The metabolism of Bromocriptine can be decreased when combined with Furazolidone.	Approved, Investigational
Bupranolol	Furazolidone may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	The risk or severity of adverse effects can be increased when Buprenorphine is combined with Furazolidone.	Approved, Illicit, Investigational, Vet Approved
Bupropion	Furazolidone may increase the hypertensive activities of Bupropion.	Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Furazolidone.	Approved, Investigational
Cabergoline	The metabolism of Cabergoline can be decreased when combined with Furazolidone.	Approved
Canagliflozin	Furazolidone may increase the hypoglycemic activities of Canagliflozin.	Approved
Candesartan	Furazolidone may increase the hypotensive activities of Candesartan.	Approved
Candoxatril	Furazolidone may increase the hypotensive activities of Candoxatril.	Experimental
Captopril	Furazolidone may increase the hypotensive activities of Captopril.	Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Furazolidone.	Approved, Investigational
Caroxazone	Furazolidone may increase the hypertensive activities of Caroxazone.	Withdrawn
Carteolol	Furazolidone may increase the hypotensive activities of Carteolol.	Approved
Carvedilol	Furazolidone may increase the hypotensive activities of Carvedilol.	Approved, Investigational
Celiprolol	Furazolidone may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Chlorothiazide	Furazolidone may increase the hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Chlorphentermine	Furazolidone may increase the hypertensive activities of Chlorphentermine.	Illicit, Withdrawn
Chlorpropamide	Furazolidone may increase the hypoglycemic activities of Chlorpropamide.	Approved
Chlorthalidone	Furazolidone may increase the hypotensive activities of Chlorthalidone.	Approved
Cilazapril	Furazolidone may increase the hypotensive activities of Cilazapril.	Approved
Cirazoline	Furazolidone may increase the hypertensive activities of Cirazoline.	Experimental
Citalopram	Furazolidone may increase the serotonergic activities of Citalopram.	Approved
Clemastine	Furazolidone may increase the anticholinergic activities of Clemastine.	Approved
Clenbuterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Clenbuterol.	Approved, Vet Approved
Clomipramine	Furazolidone may increase the serotonergic activities of Clomipramine.	Approved, Vet Approved
Clonidine	Furazolidone may increase the hypotensive activities of Clonidine.	Approved
Cryptenamine	Furazolidone may increase the hypotensive activities of Cryptenamine.	Approved
Cyclobenzaprine	Cyclobenzaprine may increase the serotonergic activities of Furazolidone.	Approved
Cyclothiazide	Furazolidone may increase the hypotensive activities of Cyclothiazide.	Approved
Cyproheptadine	Furazolidone may increase the anticholinergic activities of Cyproheptadine.	Approved
Dapagliflozin	Furazolidone may increase the hypoglycemic activities of Dapagliflozin.	Approved
Dapoxetine	Furazolidone may increase the serotonergic activities of Dapoxetine.	Investigational
Debrisoquin	Furazolidone may increase the hypotensive activities of Debrisoquin.	Approved
Deserpidine	Furazolidone may increase the hypotensive activities of Deserpidine.	Approved
Desipramine	Furazolidone may increase the serotonergic activities of Desipramine.	Approved
Desvenlafaxine	Furazolidone may increase the serotonergic activities of Desvenlafaxine.	Approved
Dexmethylphenidate	Furazolidone may increase the hypertensive activities of Dexmethylphenidate.	Approved
Dextroamphetamine	Furazolidone may increase the hypertensive activities of Dextroamphetamine.	Approved, Illicit
Dextromethorphan	Furazolidone may increase the serotonergic activities of Dextromethorphan.	Approved
Diazoxide	Furazolidone may increase the hypotensive activities of Diazoxide.	Approved
Diethylpropion	Furazolidone may increase the hypertensive activities of Diethylpropion.	Approved, Illicit
Dihydroergotamine	The metabolism of Dihydroergotamine can be decreased when combined with Furazolidone.	Approved
Diltiazem	Furazolidone may increase the hypotensive activities of Diltiazem.	Approved
Dipivefrin	The risk or severity of adverse effects can be increased when Furazolidone is combined with Dipivefrin.	Approved
Disopyramide	Furazolidone may increase the hypoglycemic activities of Disopyramide.	Approved
Dobutamine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Dobutamine.	Approved
Domperidone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone.	Approved, Investigational, Vet Approved
Dorzolamide	Furazolidone may increase the hypotensive activities of Dorzolamide.	Approved
Dosulepin	Furazolidone may increase the serotonergic activities of Dosulepin.	Approved
Doxapram	Furazolidone may increase the hypertensive activities of Doxapram.	Approved, Vet Approved
Doxazosin	Furazolidone may increase the hypotensive activities of Doxazosin.	Approved
Doxepin	Furazolidone may increase the serotonergic activities of Doxepin.	Approved
Doxylamine	Furazolidone may increase the anticholinergic activities of Doxylamine.	Approved, Vet Approved
Droxidopa	The risk or severity of adverse effects can be increased when Furazolidone is combined with Droxidopa.	Approved, Investigational
Dulaglutide	Furazolidone may increase the hypoglycemic activities of Dulaglutide.	Approved
Duloxetine	Furazolidone may increase the serotonergic activities of Duloxetine.	Approved
Efonidipine	Furazolidone may increase the hypotensive activities of Efonidipine.	Approved
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Furazolidone.	Approved, Investigational
Empagliflozin	Furazolidone may increase the hypoglycemic activities of Empagliflozin.	Approved
Enalapril	Furazolidone may increase the hypotensive activities of Enalapril.	Approved, Vet Approved
Enalaprilat	Furazolidone may increase the hypotensive activities of Enalaprilat.	Approved
Entacapone	The risk or severity of adverse effects can be increased when Entacapone is combined with Furazolidone.	Approved, Investigational
Ephedra	The risk or severity of adverse effects can be increased when Furazolidone is combined with Ephedra.	Approved, Nutraceutical, Withdrawn
Epinephrine	Furazolidone may increase the hypertensive activities of Epinephrine.	Approved, Vet Approved
Epoprostenol	Furazolidone may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	Furazolidone may increase the hypotensive activities of Eprosartan.	Approved
Ergotamine	Furazolidone may increase the hypertensive activities of Ergotamine.	Approved
Escitalopram	Furazolidone may increase the serotonergic activities of Escitalopram.	Approved, Investigational
Esmirtazapine	Furazolidone may increase the serotonergic activities of Esmirtazapine.	Investigational
Ethanol	The risk or severity of adverse effects can be increased when Ethanol is combined with Furazolidone.	Approved
Etoperidone	Furazolidone may increase the serotonergic activities of Etoperidone.	Approved
Exenatide	Furazolidone may increase the hypoglycemic activities of Exenatide.	Approved, Investigational
Felodipine	Furazolidone may increase the hypotensive activities of Felodipine.	Approved, Investigational
Fenfluramine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Fenfluramine.	Illicit, Withdrawn
Fenoldopam	Furazolidone may increase the hypotensive activities of Fenoldopam.	Approved
Fenoterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Fenoterol.	Approved
Fentanyl	Fentanyl may increase the serotonergic activities of Furazolidone.	Approved, Illicit, Investigational, Vet Approved
Fluoxetine	Furazolidone may increase the serotonergic activities of Fluoxetine.	Approved, Vet Approved
Fluvoxamine	Furazolidone may increase the serotonergic activities of Fluvoxamine.	Approved, Investigational
Formoterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Formoterol.	Approved, Investigational
Fosinopril	Furazolidone may increase the hypotensive activities of Fosinopril.	Approved
Frovatriptan	The metabolism of Frovatriptan can be decreased when combined with Furazolidone.	Approved, Investigational
Gliclazide	Furazolidone may increase the hypoglycemic activities of Gliclazide.	Approved
Glimepiride	Furazolidone may increase the hypoglycemic activities of Glimepiride.	Approved
Glipizide	Furazolidone may increase the hypoglycemic activities of Glipizide.	Approved
Glyburide	Furazolidone may increase the hypoglycemic activities of Glyburide.	Approved
Guanabenz	Furazolidone may increase the hypotensive activities of Guanabenz.	Approved
Guanadrel	Furazolidone may increase the hypotensive activities of Guanadrel.	Approved
Guanethidine	Furazolidone may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	Furazolidone may increase the hypotensive activities of Guanfacine.	Approved, Investigational
Hexamethonium	Furazolidone may increase the hypotensive activities of Hexamethonium.	Experimental
Hydracarbazine	Furazolidone may increase the hypertensive activities of Hydracarbazine.	Approved
Hydralazine	Furazolidone may increase the hypotensive activities of Hydralazine.	Approved
Hydrochlorothiazide	Furazolidone may increase the hypotensive activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Hydrocodone.	Approved, Illicit
Hydroflumethiazide	Furazolidone may increase the hypotensive activities of Hydroflumethiazide.	Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Hydromorphone.	Approved, Illicit
Hydroxyamphetamine	Furazolidone may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.	Approved
Imipramine	Furazolidone may increase the serotonergic activities of Imipramine.	Approved
Indacaterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol.	Approved
Indalpine	Furazolidone may increase the serotonergic activities of Indalpine.	Investigational, Withdrawn
Indapamide	Furazolidone may increase the hypotensive activities of Indapamide.	Approved
Indenolol	Furazolidone may increase the hypotensive activities of Indenolol.	Withdrawn
Indoramin	Furazolidone may increase the hypotensive activities of Indoramin.	Withdrawn
Insulin Aspart	Furazolidone may increase the hypoglycemic activities of Insulin Aspart.	Approved
Insulin Detemir	Furazolidone may increase the hypoglycemic activities of Insulin Detemir.	Approved
Insulin Glargine	Furazolidone may increase the hypoglycemic activities of Insulin Glargine.	Approved
Insulin Glulisine	Furazolidone may increase the hypoglycemic activities of Insulin Glulisine.	Approved
Insulin Human	Furazolidone may increase the hypoglycemic activities of Insulin Human.	Approved, Investigational
Insulin Lispro	Furazolidone may increase the hypoglycemic activities of Insulin Lispro.	Approved
Iproclozide	Furazolidone may increase the hypertensive activities of Iproclozide.	Withdrawn
Iproniazid	Furazolidone may increase the hypertensive activities of Iproniazid.	Withdrawn
Irbesartan	Furazolidone may increase the hypotensive activities of Irbesartan.	Approved, Investigational
Isocarboxazid	Furazolidone may increase the hypertensive activities of Isocarboxazid.	Approved
Isoetarine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Isoetarine.	Approved
Isometheptene	The risk or severity of adverse effects can be increased when Furazolidone is combined with Isometheptene.	Approved
Isoprenaline	The risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline.	Approved
Isradipine	Furazolidone may increase the hypotensive activities of Isradipine.	Approved
L-Tryptophan	The risk or severity of adverse effects can be increased when L-Tryptophan is combined with Furazolidone.	Approved, Nutraceutical, Withdrawn
Labetalol	Furazolidone may increase the hypotensive activities of Labetalol.	Approved
Lacidipine	Furazolidone may increase the hypotensive activities of Lacidipine.	Approved
Lanreotide	Furazolidone may increase the hypoglycemic activities of Lanreotide.	Approved
Latanoprost	Furazolidone may increase the hypotensive activities of Latanoprost.	Approved, Investigational
Lercanidipine	Furazolidone may increase the hypotensive activities of Lercanidipine.	Approved, Investigational
Levodopa	The risk or severity of adverse effects can be increased when Levodopa is combined with Furazolidone.	Approved
Levomilnacipran	Furazolidone may increase the serotonergic activities of Levomilnacipran.	Approved
Levonordefrin	Furazolidone may increase the hypertensive activities of Levonordefrin.	Approved
Linezolid	The risk or severity of adverse effects can be increased when Furazolidone is combined with Linezolid.	Approved, Investigational
Liraglutide	Furazolidone may increase the hypoglycemic activities of Liraglutide.	Approved
Lisdexamfetamine	Furazolidone may increase the hypertensive activities of Lisdexamfetamine.	Approved, Investigational
Lisinopril	Furazolidone may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Lisuride	The metabolism of Lisuride can be decreased when combined with Furazolidone.	Approved
Lithium	The risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium.	Approved
Lofexidine	Furazolidone may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Losartan	Furazolidone may increase the hypotensive activities of Losartan.	Approved
Macitentan	Furazolidone may increase the hypotensive activities of Macitentan.	Approved
Manidipine	Furazolidone may increase the hypotensive activities of Manidipine.	Approved
Maprotiline	The risk or severity of adverse effects can be increased when Maprotiline is combined with Furazolidone.	Approved
Mebanazine	Furazolidone may increase the hypertensive activities of Mebanazine.	Withdrawn
Mecamylamine	Furazolidone may increase the hypotensive activities of Mecamylamine.	Approved
Mecasermin	Furazolidone may increase the hypoglycemic activities of Mecasermin.	Approved, Investigational
Mephentermine	Furazolidone may increase the hypertensive activities of Mephentermine.	Approved
Mequitazine	Furazolidone may increase the anticholinergic activities of Mequitazine.	Approved
Metaraminol	Furazolidone may increase the hypertensive activities of Metaraminol.	Approved, Investigational
Metformin	Furazolidone may increase the hypoglycemic activities of Metformin.	Approved
Methadone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Methadone.	Approved
Methamphetamine	Furazolidone may increase the hypertensive activities of Methamphetamine.	Approved, Illicit
Methoxamine	Furazolidone may increase the hypertensive activities of Methoxamine.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Furazolidone is combined with Methyldopa.	Approved
Methylene blue	Furazolidone may increase the serotonergic activities of Methylene blue.	Investigational
Methylphenidate	Furazolidone may increase the hypertensive activities of Methylphenidate.	Approved, Investigational
Metipranolol	Furazolidone may increase the hypotensive activities of Metipranolol.	Approved
Metolazone	Furazolidone may increase the hypotensive activities of Metolazone.	Approved
Metoprolol	Furazolidone may increase the hypotensive activities of Metoprolol.	Approved, Investigational
Metyrosine	Furazolidone may increase the hypotensive activities of Metyrosine.	Approved
Mianserin	Furazolidone may increase the neurotoxic activities of Mianserin.	Approved
Mibefradil	Furazolidone may increase the hypotensive activities of Mibefradil.	Withdrawn
Midodrine	Furazolidone may increase the hypertensive activities of Midodrine.	Approved
Mifepristone	Furazolidone may increase the hypoglycemic activities of Mifepristone.	Approved, Investigational
Miglitol	Furazolidone may increase the hypoglycemic activities of Miglitol.	Approved
Milnacipran	Furazolidone may increase the serotonergic activities of Milnacipran.	Approved
Minaprine	Furazolidone may increase the hypertensive activities of Minaprine.	Approved
Minoxidil	Furazolidone may increase the hypotensive activities of Minoxidil.	Approved
Mirtazapine	Furazolidone may increase the central neurotoxic activities of Mirtazapine.	Approved
MMDA	Furazolidone may increase the hypertensive activities of MMDA.	Experimental, Illicit
Moclobemide	The risk or severity of adverse effects can be increased when Furazolidone is combined with Moclobemide.	Approved
Moexipril	Furazolidone may increase the hypotensive activities of Moexipril.	Approved
Morphine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Morphine.	Approved, Investigational
Moxonidine	Furazolidone may increase the hypotensive activities of Moxonidine.	Approved
Nadolol	Furazolidone may increase the hypotensive activities of Nadolol.	Approved
Naratriptan	The metabolism of Naratriptan can be decreased when combined with Furazolidone.	Approved, Investigational
Nateglinide	Furazolidone may increase the hypoglycemic activities of Nateglinide.	Approved, Investigational
Nebivolol	Furazolidone may increase the hypotensive activities of Nebivolol.	Approved, Investigational
Nefazodone	Furazolidone may increase the serotonergic activities of Nefazodone.	Approved, Withdrawn
Nialamide	Furazolidone may increase the hypertensive activities of Nialamide.	Withdrawn
Nicardipine	Furazolidone may increase the hypotensive activities of Nicardipine.	Approved
Nicorandil	Furazolidone may increase the hypotensive activities of Nicorandil.	Approved
Niguldipine	Furazolidone may increase the hypotensive activities of Niguldipine.	Experimental
Nilvadipine	Furazolidone may increase the hypotensive activities of Nilvadipine.	Approved
Nimodipine	Furazolidone may increase the hypotensive activities of Nimodipine.	Approved
Nisoldipine	Furazolidone may increase the hypotensive activities of Nisoldipine.	Approved
Nitrendipine	Furazolidone may increase the hypotensive activities of Nitrendipine.	Approved
Nitroprusside	Furazolidone may increase the hypotensive activities of Nitroprusside.	Approved
Norepinephrine	Furazolidone may increase the hypertensive activities of Norepinephrine.	Approved
Nortriptyline	Furazolidone may increase the serotonergic activities of Nortriptyline.	Approved
Octamoxin	Furazolidone may increase the hypertensive activities of Octamoxin.	Withdrawn
Octreotide	Furazolidone may increase the hypoglycemic activities of Octreotide.	Approved, Investigational
Olanzapine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Olanzapine.	Approved, Investigational
Olmesartan	Furazolidone may increase the hypotensive activities of Olmesartan.	Approved, Investigational
Olodaterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Olodaterol.	Approved
Omapatrilat	Furazolidone may increase the hypotensive activities of Omapatrilat.	Investigational
Orciprenaline	The risk or severity of adverse effects can be increased when Furazolidone is combined with Orciprenaline.	Approved
Oxprenolol	Furazolidone may increase the hypotensive activities of Oxprenolol.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Furazolidone.	Approved, Investigational, Vet Approved
Pargyline	Furazolidone may increase the hypertensive activities of Pargyline.	Approved
Paroxetine	Furazolidone may increase the serotonergic activities of Paroxetine.	Approved, Investigational
Pasireotide	Furazolidone may increase the hypoglycemic activities of Pasireotide.	Approved
Penbutolol	Furazolidone may increase the hypotensive activities of Penbutolol.	Approved, Investigational
Pentamidine	Furazolidone may increase the hypoglycemic activities of Pentamidine.	Approved
Pentolinium	Furazolidone may increase the hypotensive activities of Pentolinium.	Approved
Pergolide	The metabolism of Pergolide can be decreased when combined with Furazolidone.	Approved, Vet Approved, Withdrawn
Perindopril	Furazolidone may increase the hypotensive activities of Perindopril.	Approved
Pethidine	Furazolidone may increase the serotonergic activities of Pethidine.	Approved
Phenelzine	Furazolidone may increase the hypertensive activities of Phenelzine.	Approved
Pheniprazine	Furazolidone may increase the hypertensive activities of Pheniprazine.	Withdrawn
Phenoxybenzamine	Furazolidone may increase the hypotensive activities of Phenoxybenzamine.	Approved
Phenoxypropazine	Furazolidone may increase the hypertensive activities of Phenoxypropazine.	Withdrawn
Phentermine	Furazolidone may increase the hypertensive activities of Phentermine.	Approved, Illicit
Phentolamine	Furazolidone may increase the hypotensive activities of Phentolamine.	Approved
Phenylephrine	Furazolidone may increase the hypertensive activities of Phenylephrine.	Approved
Phenylpropanolamine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Phenylpropanolamine.	Approved, Vet Approved, Withdrawn
Pholcodine	Pholcodine may increase the serotonergic activities of Furazolidone.	Approved, Illicit
Pindolol	Furazolidone may increase the hypotensive activities of Pindolol.	Approved
Pioglitazone	Furazolidone may increase the hypoglycemic activities of Pioglitazone.	Approved, Investigational
Pirbuterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Pirbuterol.	Approved
Pirlindole	Furazolidone may increase the hypertensive activities of Pirlindole.	Approved
Pivhydrazine	Furazolidone may increase the hypertensive activities of Pivhydrazine.	Withdrawn
Polythiazide	Furazolidone may increase the hypotensive activities of Polythiazide.	Approved
Pramlintide	Furazolidone may increase the hypoglycemic activities of Pramlintide.	Approved, Investigational
Prazosin	Furazolidone may increase the hypotensive activities of Prazosin.	Approved
Procaterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Procaterol.	Approved
Propranolol	Furazolidone may increase the hypotensive activities of Propranolol.	Approved, Investigational
Protriptyline	Furazolidone may increase the serotonergic activities of Protriptyline.	Approved
Pseudoephedrine	Furazolidone may increase the hypertensive activities of Pseudoephedrine.	Approved
Quinapril	Furazolidone may increase the hypotensive activities of Quinapril.	Approved, Investigational
Quinine	Furazolidone may increase the hypoglycemic activities of Quinine.	Approved
Ramipril	Furazolidone may increase the hypotensive activities of Ramipril.	Approved
Rasagiline	Furazolidone may increase the hypertensive activities of Rasagiline.	Approved
Remifentanil	Remifentanil may increase the serotonergic activities of Furazolidone.	Approved
Remikiren	Furazolidone may increase the hypotensive activities of Remikiren.	Approved
Repaglinide	Furazolidone may increase the hypoglycemic activities of Repaglinide.	Approved, Investigational
Rescinnamine	Furazolidone may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Reserpine.	Approved
Riociguat	Furazolidone may increase the hypotensive activities of Riociguat.	Approved
Ritodrine	The risk or severity of adverse effects can be increased when Furazolidone is combined with Ritodrine.	Approved
Rizatriptan	The metabolism of Rizatriptan can be decreased when combined with Furazolidone.	Approved
Ropinirole	The metabolism of Ropinirole can be decreased when combined with Furazolidone.	Approved, Investigational
Rosiglitazone	Furazolidone may increase the hypoglycemic activities of Rosiglitazone.	Approved, Investigational
Safrazine	Furazolidone may increase the hypertensive activities of Safrazine.	Withdrawn
Salbutamol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol.	Approved, Vet Approved
Salmeterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Salmeterol.	Approved
Saprisartan	Furazolidone may increase the hypotensive activities of Saprisartan.	Experimental
Saxagliptin	Furazolidone may increase the hypoglycemic activities of Saxagliptin.	Approved
Selegiline	Furazolidone may increase the hypertensive activities of Selegiline.	Approved, Investigational, Vet Approved
Selexipag	Furazolidone may increase the hypotensive activities of Selexipag.	Approved
Sertraline	Furazolidone may increase the serotonergic activities of Sertraline.	Approved
Sitagliptin	Furazolidone may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Sitaxentan	Furazolidone may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Spirapril	Furazolidone may increase the hypotensive activities of Spirapril.	Approved
Sufentanil	Sufentanil may increase the serotonergic activities of Furazolidone.	Approved, Investigational
Sulfadiazine	Furazolidone may increase the hypoglycemic activities of Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	Furazolidone may increase the hypoglycemic activities of Sulfamethoxazole.	Approved
Sulfisoxazole	Furazolidone may increase the hypoglycemic activities of Sulfisoxazole.	Approved, Vet Approved
Sumatriptan	The metabolism of Sumatriptan can be decreased when combined with Furazolidone.	Approved, Investigational
Sunitinib	Furazolidone may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Tapentadol	The risk or severity of adverse effects can be increased when Tapentadol is combined with Furazolidone.	Approved
Telmisartan	Furazolidone may increase the hypotensive activities of Telmisartan.	Approved, Investigational
Temocapril	Furazolidone may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Terbutaline	The risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline.	Approved
Terlipressin	Furazolidone may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Testosterone Propionate	The risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Furazolidone.	Approved, Vet Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Furazolidone.	Approved
Tetryzoline	Furazolidone may increase the hypertensive activities of Tetryzoline.	Approved
Tianeptine	The risk or severity of adverse effects can be increased when Tianeptine is combined with Furazolidone.	Approved
Tibolone	Furazolidone may increase the hypotensive activities of Tibolone.	Approved
Ticrynafen	Furazolidone may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	Furazolidone may increase the hypotensive activities of Timolol.	Approved
Tolazamide	Furazolidone may increase the hypoglycemic activities of Tolazamide.	Approved
Tolazoline	Furazolidone may increase the hypotensive activities of Tolazoline.	Approved, Vet Approved
Tolbutamide	Furazolidone may increase the hypoglycemic activities of Tolbutamide.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Furazolidone.	Approved, Withdrawn
Toloxatone	Furazolidone may increase the hypertensive activities of Toloxatone.	Approved
Torasemide	Furazolidone may increase the hypotensive activities of Torasemide.	Approved
Tramadol	Tramadol may increase the neuroexcitatory activities of Furazolidone.	Approved, Investigational
Trandolapril	Furazolidone may increase the hypotensive activities of Trandolapril.	Approved
Trans-2-Phenylcyclopropylamine	Furazolidone may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	Furazolidone may increase the hypertensive activities of Tranylcypromine.	Approved
Travoprost	Furazolidone may increase the hypotensive activities of Travoprost.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Trazodone.	Approved, Investigational
Treprostinil	Furazolidone may increase the hypotensive activities of Treprostinil.	Approved, Investigational
Trichlormethiazide	Furazolidone may increase the hypotensive activities of Trichlormethiazide.	Approved, Vet Approved
Trimazosin	Furazolidone may increase the hypotensive activities of Trimazosin.	Experimental
Trimethaphan	Furazolidone may increase the hypotensive activities of Trimethaphan.	Approved
Trimipramine	Furazolidone may increase the serotonergic activities of Trimipramine.	Approved
Unoprostone	Furazolidone may increase the hypotensive activities of Unoprostone.	Approved
Valsartan	Furazolidone may increase the hypotensive activities of Valsartan.	Approved, Investigational
Venlafaxine	Furazolidone may increase the serotonergic activities of Venlafaxine.	Approved
Vilanterol	The risk or severity of adverse effects can be increased when Furazolidone is combined with Vilanterol.	Approved
Vilazodone	The metabolism of Vilazodone can be decreased when combined with Furazolidone.	Approved
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Furazolidone.	Approved
Xylometazoline	Furazolidone may increase the hypotensive activities of Xylometazoline.	Approved
Zimelidine	Furazolidone may increase the serotonergic activities of Zimelidine.	Withdrawn
Zolmitriptan	The metabolism of Zolmitriptan can be decreased when combined with Furazolidone.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company.

US2742462

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14752
KEGG Drug	D00830
KEGG Compound	C07999
PubChem Compound	3435
PubChem Substance	46507291
ChemSpider	4481255
ChEBI	5195
ChEMBL	CHEMBL1103
Therapeutic Targets Database	DAP000993
PharmGKB	PA164746760
Drug Product Database	10161
RxList	http://www.rxlist.com/cgi/generic2/furazol.htm
Drugs.com	http://www.drugs.com/cons/furazolidone.html
Wikipedia	Furazolidone

ATC Codes

G01AX06

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (74.1 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Functional Dyspepsia / Scarred Peptic Ulcer	1
4	Not Yet Recruiting	Treatment	Antimicrobial Susceptibility Testing / Triple Therapy	1
4	Recruiting	Treatment	Antimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
4	Recruiting	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
Not Available	Completed	Treatment	Treatment of Helicobacter Pylori	1

Pharmacoeconomics

Manufacturers

Shire development inc

Packagers

Professional Co.

Dosage forms

Not Available

Prices

Unit description	Cost	Unit
Furazolidone powder	2.04USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	254-256	Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company
water solubility	40 mg/L (at 25 °C)	MERCK INDEX (1996); pH 6
logP	-0.04	DEBNATH,AK ET AL. (1991)

Predicted Properties

Property	Value	Source
Water Solubility	0.364 mg/mL	ALOGPS
logP	0.15	ALOGPS
logP	0.87	ChemAxon
logS	-2.8	ALOGPS
pKa (Strongest Basic)	-2.4	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	100.86 Å²	ChemAxon
Rotatable Bond Count	3	ChemAxon
Refractivity	51.09 m³·mol^-1	ChemAxon
Polarizability	19.74 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9038
Blood Brain Barrier	+	0.9117
Caco-2 permeable	-	0.5736
P-glycoprotein substrate	Non-substrate	0.7829
P-glycoprotein inhibitor I	Non-inhibitor	0.7761
P-glycoprotein inhibitor II	Non-inhibitor	0.9597
Renal organic cation transporter	Non-inhibitor	0.8351
CYP450 2C9 substrate	Non-substrate	0.8117
CYP450 2D6 substrate	Non-substrate	0.8415
CYP450 3A4 substrate	Substrate	0.5984
CYP450 1A2 substrate	Inhibitor	0.9107
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9134
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.928
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8828
Ames test	AMES toxic	0.9108
Carcinogenicity	Non-carcinogens	0.9097
Biodegradation	Ready biodegradable	0.8978
Rat acute toxicity	2.1639 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7889
hERG inhibition (predictor II)	Non-inhibitor	0.9057

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as nitrofurans. These are compounds containing a furan ring which bears a nitro group.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Furans

Direct Parent

Nitrofurans

Alternative Parents

Nitroaromatic compounds / Oxazolidinones / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides

Substituents

Nitroaromatic compound / 2-nitrofuran / Oxazolidinone / Oxazolidine / Heteroaromatic compound / C-nitro compound / Organic nitro compound / Organic oxoazanium / Oxacycle / Azacycle

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

oxazolidines, nitrofuran antibiotic (CHEBI:5195 )

Targets

1. DNA

Kind: Nucleotide
Organism: Human
Pharmacological action: yes
Actions: cross-linking/alkylation

General Function:: Used for biological information storage.
Specific Function:: DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:: 2.15 x 10¹² Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Meng J, Mangat SS, Grudzinski IP, Law FC: Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout. Drug Metabol Drug Interact. 1998;14(4):209-19. [PubMed:10694929 ]

Enzymes

Details

1. Amine oxidase [flavin-containing] B

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Primary amine oxidase activity
Specific Function:: Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:: MAOB
Uniprot ID:: P27338
Molecular Weight:: 58762.475 Da

References

Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758 ]
Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364 ]
Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659 ]

Details

2. Amine oxidase [flavin-containing] A

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Serotonin binding
Specific Function:: Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:: MAOA
Uniprot ID:: P21397
Molecular Weight:: 59681.27 Da

References

Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758 ]
Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364 ]
Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659 ]

Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 15:40

Get DrugBank to go!

Structure for DB00614 (Furazolidone)

Targets

References

Enzymes

References

References